The global COVID-19 testing kits market size was valued at USD 2.76 billion in 2025 and is projected to grow from USD 3.24 billion in 2026 to USD 11.69 billion by 2034, registering a CAGR of 17.4% during the forecast period from 2026 to 2034. North America dominated the COVID-19 testing kits market with a market share of 38.5% in 2025.
COVID-19 testing kits are diagnostic tools used to detect the presence of the SARS-CoV-2 virus or antibodies produced in response to infection. They include molecular (PCR), rapid antigen, and antibody tests, each serving different diagnostic purposes. These kits enable early detection, timely treatment, and effective disease surveillance, helping reduce the spread of COVID-19 in healthcare settings, workplaces, and communities.
Download a Free Sample To learn more about this report,
Expansion of Variant-Aware and Flexible Diagnostic Platforms
COVID-19 testing technologies are increasingly being designed to remain useful as SARS-CoV-2 variants and circulating respiratory pathogens change over time. Diagnostic developers are therefore emphasizing assays with multiple molecular targets, adaptable test designs, and platforms that can accommodate updated targets without requiring entirely new laboratory infrastructure. This structural shift improves the resilience of COVID-19 testing systems and reduces dependence on a single viral target as disease characteristics evolve. WHO continues to emphasize linking COVID-19 testing with genomic surveillance and monitoring viral evolution.
Shift Toward Rapid and Decentralized COVID-19 Testing
The market is also shifting toward diagnostic solutions that can deliver results closer to the patient rather than relying exclusively on centralized laboratory workflows. Faster molecular and antigen-based systems can support earlier clinical decisions and improve access to testing in settings where laboratory infrastructure is limited. This structural transition is increasing the importance of portability, ease of use, and rapid turnaround alongside analytical performance. WHO continues to recommend accessible, quality-assured COVID-19 diagnostics as part of long-term disease management.
Persistent Need for Clinical Diagnosis of Symptomatic Respiratory Infections
The COVID-19 testing kits market continues to receive demand from healthcare systems that need to distinguish COVID-19 from other respiratory illnesses when diagnosis affects treatment, isolation, or patient management. Testing remains particularly relevant for people at higher risk of severe disease because early identification can facilitate timely access to appropriate care and therapeutics. As COVID-19 becomes part of longer-term respiratory disease management, demand is shifting from emergency mass testing toward targeted clinical testing.
Declining Emergency Testing Volumes Reduce Large-Scale Procurement
The market faces a structural restraint from the transition away from pandemic-era mass testing programs toward targeted and routine testing. Government procurement, institutional screening, and large-scale testing initiatives have become less central as health systems move toward long-term COVID-19 management. This reduces volume visibility for manufacturers and increases pressure to operate efficiently in a smaller and more clinically focused testing market. WHO's shift toward integrated, risk-based COVID-19 management reflects this transition.
Expansion of COVID-19 Testing in High-Risk and Underserved Populations
A distinct opportunity exists in improving access to COVID-19 diagnostics for populations that face barriers to timely laboratory testing, particularly people at elevated risk of severe disease and communities with limited diagnostic infrastructure. Portable, self-testing, and decentralized solutions can extend diagnostic access without requiring the same laboratory capacity as centralized testing. This creates commercial whitespace around accessibility and care delivery rather than simply adding additional respiratory pathogens to a test panel. WHO specifically emphasizes equitable access to safe, effective, and quality-assured diagnostics.
Maintaining Diagnostic Accuracy as Viral Characteristics and Testing Conditions Change
COVID-19 testing manufacturers must maintain reliable diagnostic performance as viral variants evolve and testing moves across different clinical and decentralized settings. Changes in circulating variants can affect assay targets, while differences in specimen collection, timing, and user technique can influence results. Maintaining analytical sensitivity, quality assurance, regulatory compliance, and reliable performance across these conditions remains a major technical challenge. WHO continues to link COVID-19 testing with genomic surveillance and assessment of changes in SARS-CoV-2 characteristics.
RT-PCR Assay Kits Dominated the Market with 61.4% Share in 2025
The RT-PCR assay kits segment accounted for the largest share of the global COVID-19 testing kits market at 61.4% in 2025, driven by their high diagnostic accuracy, superior sensitivity, and widespread adoption as the gold standard for SARS-CoV-2 detection across hospitals, laboratories, and public health agencies.
Immunoassay test strips and cassettes are witnessing steady growth due to their rapid turnaround time, ease of use, and increasing adoption for point-of-care testing, mass screening programs, and home-based diagnostic applications.
Request Customizationto receive a tailored report.
Nasal Swab is Projected to Register the Fastest Growth at a CAGR of 5.6%
The nasal swab segment is expected to expand at the highest CAGR of 5.6% during 2026–2034, supported by increasing preference for less invasive sample collection methods, improved patient comfort, and expanding use in rapid diagnostic and self-testing kits.
Nasopharyngeal swabs continue to account for the largest share of diagnostic testing due to their high accuracy and widespread use in clinical laboratories. Oropharyngeal swabs remain an important specimen type for COVID-19 testing, particularly in healthcare settings where alternative sampling methods are required.
Hospitals Dominated the Market with 57.3% Share in 2025
The hospitals segment accounted for the largest share of the global COVID-19 testing kits market at 57.3% in 2025, driven by the high volume of diagnostic testing conducted for patient screening, emergency care, inpatient management, infection control, and routine surveillance during disease outbreaks.
Diagnostic centers continue to witness steady growth as they expand laboratory testing capacity, improve access to molecular and rapid diagnostic services, and support large-scale community screening programs with advanced testing technologies.
Speak to an Analystto discuss market opportunities.
North America market accounted for 38.5% of the global COVID-19 testing kits market, valued at USD 1.06 billion in 2025. The region's growth is driven by advanced healthcare infrastructure, increasing demand for rapid and molecular diagnostic testing, expanding investments in infectious disease surveillance, and strong government support for public health preparedness. Continuous innovation in diagnostic technologies and growing adoption of point-of-care testing continue to support regional market growth.
The United States market accounted for the largest share of the North American market in 2025. Growth is driven by increasing demand for rapid diagnostic tests, expanding laboratory testing capacity, rising investments in disease surveillance programmes, and the presence of leading diagnostic manufacturers. Continuous advancements in molecular diagnostics and point-of-care testing further strengthen the country's market position.
Canada market is witnessing steady market growth due to increasing investments in public healthcare, expanding diagnostic laboratory infrastructure, rising adoption of rapid testing technologies, and growing focus on preparedness for infectious disease outbreaks.
Unlock Regional Insightsto access country-level data, & regional trends.
The European market accounted for 27.2% of the global COVID-19 testing kits market, reaching USD 0.75 billion in 2025. Market growth is supported by increasing investments in public health systems, expanding diagnostic testing capabilities, rising adoption of rapid antigen and molecular tests, and growing emphasis on infectious disease monitoring. Continuous innovation in diagnostic technologies continues to drive regional demand.
The United Kingdom market is witnessing steady market growth owing to increasing investments in healthcare diagnostics, expanding disease surveillance programmes, rising demand for rapid testing solutions, and growing adoption of advanced molecular diagnostic technologies.
Germany market represents one of the largest markets in Europe, driven by its advanced healthcare infrastructure, increasing diagnostic testing capacity, strong biotechnology sector, and continuous investments in innovative infectious disease diagnostic solutions.
Asia Pacific market accounted for 24.8% of the global COVID-19 testing kits market, valued at USD 0.68 billion in 2025, and is projected to register the fastest CAGR of 6.2% during the forecast period. The market is expanding due to increasing healthcare expenditure, growing awareness of infectious disease prevention, expanding diagnostic infrastructure, and rising government initiatives to strengthen public health systems. Continuous improvements in laboratory capacity and diagnostic technologies continue to support regional market growth.
Japan market is witnessing steady market growth due to increasing adoption of advanced molecular diagnostic technologies, expanding healthcare investments, growing focus on disease surveillance, and continuous improvements in laboratory testing capabilities.
China market accounted for the largest share of the Asia Pacific market in 2025. Growth is supported by expanding diagnostic manufacturing capacity, increasing investments in healthcare infrastructure, rising demand for rapid testing solutions, and strong government initiatives to strengthen infectious disease monitoring and response.
The Middle East & Africa market represented 3.9% of the global COVID-19 testing kits market, totaling USD 0.11 billion in 2025. Rising investments in healthcare infrastructure, expanding diagnostic laboratory networks, increasing awareness of infectious disease detection, and growing government support for public health preparedness are supporting regional market growth.
The UAE market is a key market in the Middle East, driven by increasing investments in advanced healthcare infrastructure, expanding diagnostic testing capabilities, growing adoption of rapid testing technologies, and strong government initiatives supporting disease surveillance and public health management.
Africa market is witnessing gradual market growth, supported by expanding access to diagnostic services, increasing healthcare investments, rising public health awareness, and growing collaborations with international healthcare organizations. Countries such as South Africa, Kenya, and Nigeria are creating long-term growth opportunities for market participants.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Asia Pacific Electrocardiograph (ECG) Market Size, Share Trend Analysis by 2034
Middle East and Africa Dental Intraoral Scanners Market Size, 2034
Artificial Lung Market Size, Share, Growth, Analysis, 2034
Bronchoscopes Market Size, Share, Growth, Analysis, Report, 2034
Aesthetic Threads Market Size, Share, Growth, Forecast, 2034
Middle East And Africa Diabetes Devices Market Size and Forecast 2034
We are featured on:
sales@straitsresearch.com